Paper36930674
Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis.
COVID-19 Forecasting Team. Lancet, 2023. Cited by 318 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Papers, record 36930674. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36930674
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| United States | |
| Humans | |
| Bayes Theorem | |
| Prospective Studies | |
| Reinfection | |
| Retrospective Studies | |
| SARS-CoV-2 |
Source PubMed
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 36,930,672 | COVID-19 infection, reinfection, and the transition to endemicity. | https://conductscience.org/library/papers/36930672 | PubMed |
| Comment in | 37,777,328 | Extra data to confirm waning protection of omicron (B.1.1.529) natural immunity. | https://conductscience.org/library/papers/37777328 | PubMed |
| Comment in | 37,777,331 | Natural SARS-CoV-2 infection-induced immune protection against re-infection. | https://conductscience.org/library/papers/37777331 | PubMed |
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34,043,841 | Quantifying the risk of SARS-CoV-2 reinfection over time. | Rev Med Virol | 2022 | https://conductscience.org/library/papers/34043841 | PubMed |
| 2 | 32,668,444 | SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. | Nature | 2020 | https://conductscience.org/library/papers/32668444 | PubMed |
| 3 | 34,592,838 | A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection. | Eval Health Prof | 2021 | https://conductscience.org/library/papers/34592838 | PubMed |
| 4 | 33,686,204 | A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). | Nat Hum Behav | 2021 | https://conductscience.org/library/papers/33686204 | PubMed |
| 5 | 33,450,303 | Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months. | J Infect | 2021 | https://conductscience.org/library/papers/33450303 | PubMed |
| 6 | 34,908,003 | Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. | Chin Med J (Engl) | 2022 | https://conductscience.org/library/papers/34908003 | PubMed |
| 7 | 35,945,213 | Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. | Nat Commun | 2022 | https://conductscience.org/library/papers/35945213 | PubMed |
| 8 | 34,954,658 | Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. | EBioMedicine | 2022 | https://conductscience.org/library/papers/34954658 | PubMed |
| 9 | 32,434,945 | DNA vaccine protection against SARS-CoV-2 in rhesus macaques. | Science | 2020 | https://conductscience.org/library/papers/32434945 | PubMed |
| 10 | 32,943,637 | A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. | Nat Commun | 2020 | https://conductscience.org/library/papers/32943637 | PubMed |
| 11 | 35,279,232 | Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. | Lancet | 2022 | https://conductscience.org/library/papers/35279232 | PubMed |
| 12 | 32,955,556 | Pandemic Politics: Timing State-Level Social Distancing Responses to COVID-19. | J Health Polit Policy Law | 2021 | https://conductscience.org/library/papers/32955556 | PubMed |
| 13 | 35,133,177 | Rapid increase in Omicron infections in England during December 2021: REACT-1 study. | Science | 2022 | https://conductscience.org/library/papers/35133177 | PubMed |
| 14 | 35,149,106 | SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. | Environ Res | 2022 | https://conductscience.org/library/papers/35149106 | PubMed |
| 15 | 33,140,086 | Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. | J Infect Dis | 2021 | https://conductscience.org/library/papers/33140086 | PubMed |
| 16 | 35,961,956 | Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. | Nat Commun | 2022 | https://conductscience.org/library/papers/35961956 | PubMed |
| 17 | 36,198,139 | Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. | N Engl J Med | 2022 | https://conductscience.org/library/papers/36198139 | PubMed |
| 18 | 36,152,671 | Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. | Lancet Infect Dis | 2023 | https://conductscience.org/library/papers/36152671 | PubMed |
| 19 | 34,914,115 | Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. | J Med Virol | 2022 | https://conductscience.org/library/papers/34914115 | PubMed |
| 20 | 33,493,185 | T cell response to SARS-CoV-2 infection in humans: A systematic review. | PLoS One | 2021 | https://conductscience.org/library/papers/33493185 | PubMed |
Cited by246
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 318 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,818,453 | Longitudinal antibody correlates of SARS-CoV-2 infection in a US household cohort during Omicron waves. | medRxiv | 2026 | https://conductscience.org/library/papers/42818453 | PubMed |
| 42,811,742 | Real-world evaluation of 2023-2024 XBB.1.5 mRNA and protein-based COVID-19 vaccine reactogenicity from the randomized BEEHIVE trial. | Hum Vaccin Immunother | 2026 | https://conductscience.org/library/papers/42811742 | PubMed |
| 42,745,337 | Travel vaccination in senior travelers: current evidence, challenges, and prevention. | Trop Dis Travel Med Vaccines | 2026 | https://conductscience.org/library/papers/42745337 | PubMed |
| 42,442,743 | Reassessing Early COVID-19 Strategies in East Asia: Insights From Japan and Korea. | J Prev Med Public Health | 2026 | https://conductscience.org/library/papers/42442743 | PubMed |
| 42,369,736 | Assessing risk of COVID-19 reinfection and complications in adults treated with stimulant medications: A retrospective study using electronic health records. | Med Res Arch | 2024 | https://conductscience.org/library/papers/42369736 | PubMed |
| 42,347,641 | Characteristics of SARS-CoV-2 Reinfection and Ancestral RBD-Blocking Antibody Levels: A Cross-Sectional Study in the Post-Zero-COVID Era from Shanghai. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42347641 | PubMed |
| 42,188,767 | Hybrid and Vaccine-Induced Immunity Against SARS-CoV-2 in a Cohort of Hospitalized Patients from the Metropolitan Aburrá Valley, Colombia. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42188767 | PubMed |
| 42,173,827 | SARS-CoV-2 infection and vaccination elicit distinct pharyngeal mucosal B cell responses in children. | Nat Commun | 2026 | https://conductscience.org/library/papers/42173827 | PubMed |
| 42,129,996 | How does prior infection and vaccination relate to the risk of incident SARS-CoV-2 infection/reinfection? A prospective cohort study among nine clinical sites in the USA, February 2021 to January 2023. | BMJ Open | 2026 | https://conductscience.org/library/papers/42129996 | PubMed |
| 42,094,075 | Epidemiological Trends of COVID-19 Infection and Symptom Incidence in China Following the Adjustment of Zero-COVID Policy: A Prospective, Community-Based Cohort Study. | Transbound Emerg Dis | 2026 | https://conductscience.org/library/papers/42094075 | PubMed |
| 41,812,140 | Prevalence and Factors Associated With Acute Stress Disorder Among Adults Ever Infected With COVID-19 During the Ending Phase of the Pandemic in 7 Chinese Cities: Cross-Sectional Study. | JMIR Public Health Surveill | 2026 | https://conductscience.org/library/papers/41812140 | PubMed |
| 41,803,122 | Infection-acquired protection against SARS-CoV-2 infection and clinical severity by number of prior infections. | Nat Commun | 2026 | https://conductscience.org/library/papers/41803122 | PubMed |
| 41,746,093 | Challenges and Prospects in the Development of a Universal SARS-CoV-2 Vaccine. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/41746093 | PubMed |
| 41,746,085 | A Reanalysis of the FDA's Benefit-Risk Assessment of Moderna's mRNA-1273 COVID Vaccine Based on a Model Incorporating Benefits Derived from Prior COVID Infection. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/41746085 | PubMed |
| 41,613,763 | Natural Selection-Guided ACE2-Targeted Molecular Imaging: A New Paradigm for PET Tracer Development. | Chem Biomed Imaging | 2026 | https://conductscience.org/library/papers/41613763 | PubMed |
| 41,527,184 | Early COVID-19 and Severity of Subsequent Omicron Infection in Ontario Canada. | Influenza Other Respir Viruses | 2026 | https://conductscience.org/library/papers/41527184 | PubMed |
| 41,466,249 | Hybrid, infection- and vaccination-induced protection against laboratory- confirmed SARS-CoV-2 infection in a European multi-centre prospective cohort of healthcare workers, 2021-2024. | BMC Med | 2025 | https://conductscience.org/library/papers/41466249 | PubMed |
| 41,347,851 | Assessing SARS-CoV-2 transmission in African households from the reanalysis of serosurveys. | Am J Epidemiol | 2026 | https://conductscience.org/library/papers/41347851 | PubMed |
| 41,332,493 | [The Suspected Coronavirus Disease 2019 Reinfection Cases and Vaccine Effectiveness, The Republic of Korea]. | Jugan Geongang Gwa Jilbyeong | 2023 | https://conductscience.org/library/papers/41332493 | PubMed |
| 41,272,190 | Humoral immunity and clinical characteristics of Chinese college students experiencing a BA.5/BF.7 and XBB.1.5 wave. | Sci Rep | 2025 | https://conductscience.org/library/papers/41272190 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| NFKB1 | 4,790 | PubTator's text mining | https://conductscience.org/library/genes/4790 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36930674
GET https://conductscience.org/api/papers/v1/36930674/references?page=2